The UK Pompe Consortium's five academic centres and the NHS's eight Highly Specialised Service sites concentrate expertise around a six-physician BIMDG subcommittee that advises NICE directly.
UK Pompe disease expertise concentrates around a defined academic-clinical network, not a broad national field. The UK Pompe Consortium coordinates shared care, a national registry, and research across five centres: GSTT/King's, Manchester, Birmingham, Addenbrooke's, and Edinburgh. Enzyme replacement therapy is delivered through the NHS Pompe Highly Specialised Service, eight centres nationally, anchored by Royal Free London's cohort of roughly 80 to 100 patients, the network's single largest concentration. A coordinated, registry-backed academic network of this kind does not form without an established referral and collaboration structure. Our KOL Universe gate (K1) starts by mapping exactly this kind of institutional concentration before any single physician is scored.
That structure changes how AXLRx tiers influence in the UK. A metabolic physician sitting on the British Inherited Metabolic Disease Group's Pompe subcommittee, six physicians drawn from across the eight NHS Highly Specialised Service centres who advise NICE directly, carries a different weight than one working outside that advisory structure, and our Tier Classification gate (K2) scores that distinction directly, alongside FVC/6MWT monitoring capability and NICE-facing institutional roles. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live publication records and institutional affiliations, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a physician with no real influence over NICE-facing peers, which is exactly what the K1-K6 gate structure is built to prevent.
The UK Pompe Consortium and NHS Highly Specialised Service network — five academic centres, eight treatment sites
| Institution | Role | Network |
|---|---|---|
| Guy's and St Thomas' / King's College Hospital | Adult metabolic disease, shared care | UK Pompe Consortium |
| Manchester (Manchester Centre for Genomic Medicine) | GAA enzyme assay site, shared care | UK Pompe Consortium |
| Birmingham | GAA enzyme assay site, shared care | UK Pompe Consortium |
| Addenbrooke's, Cambridge | Shared care, metabolic genetics | UK Pompe Consortium |
| Edinburgh (Queen Elizabeth) | Shared care, metabolic genetics | UK Pompe Consortium |
| Royal Free London | Largest single patient cohort (~80-100 patients) | NHS Pompe Highly Specialised Service |
Sources: UK Pompe Consortium registry 2023; UK Pompe Consortium diagnostic pathway guidelines 2022; NHS England Pompe Highly Specialised Service specification; BIMDG Pompe subcommittee guidance.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The UK Pompe Consortium's five-centre academic network
- The eight-centre NHS Highly Specialised Service structure
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- BIMDG Pompe subcommittee membership and NICE-advisory weighting
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- Live publication and institutional-affiliation cross-checks
- Why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the UK Pompe Consortium and NHS Highly Specialised Service case before the rest of the workbook is built out
- Every UK Pompe disease KOL sized and sourced from publication and institutional-affiliation data
- The UK Pompe Consortium's five-centre network and the NHS's eight Highly Specialised Service sites as the sizing anchor
- Universe boundaries: who counts as a KOL versus a high-volume prescriber
- Scientific and advisory-influence scoring across BIMDG Pompe subcommittee membership and NICE-facing institutional roles
- What separates a Tier 1 KOL from a high-volume community prescriber
- Influence inputs: NICE-facing advisory role, FVC/6MWT monitoring capability, institutional role
- Cross-checked against independent publication and citation data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
- Territory-to-KOL coverage map across the UK Pompe Consortium and NHS HSS centres
- Where current MSL deployment has gaps
- Multi-market reach for KOLs active beyond the UK, across EU5 metabolic disease networks
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live publication records and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.
UK Pompe disease KOL sources: UK Pompe Consortium registry 2023, UK Pompe Consortium diagnostic pathway guidelines 2022, NHS England Pompe Highly Specialised Service specification, and BIMDG Pompe subcommittee guidance.
- UK Pompe Consortium centre list verified against UK Pompe Consortium registry 2023
- NHS Pompe Highly Specialised Service centre count and Royal Free London cohort size verified against NHS England Pompe Highly Specialised Service specification
- BIMDG Pompe subcommittee membership count verified against BIMDG Pompe subcommittee guidance
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging UK Pompe disease specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.